{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:43:34Z","timestamp":1792755814899,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020884","name":"ANID","doi-asserted-by":"publisher","award":["72180406"],"award-info":[{"award-number":["72180406"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLD015"],"award-info":[{"award-number":["SLD015"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLD016"],"award-info":[{"award-number":["SLD016"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PI17\/01518"],"award-info":[{"award-number":["PI17\/01518"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PI20\/00093"],"award-info":[{"award-number":["PI20\/00093"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["PI18\/01332"],"award-info":[{"award-number":["PI18\/01332"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015439","name":"Instituci\u00f3 CERCA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI20\/00093"],"award-info":[{"award-number":["PI20\/00093"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI17\/01518"],"award-info":[{"award-number":["PI17\/01518"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI18\/01332"],"award-info":[{"award-number":["PI18\/01332"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.xcrm.2022.100523","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T02:30:50Z","timestamp":1642991450000},"page":"100523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-8920","authenticated-orcid":false,"given":"Edwards","family":"Pradenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Trinit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marfil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Tarr\u00e9s-Freixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Rovirosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Vergara-Alert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Segal\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Guallar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-1821","authenticated-orcid":false,"given":"Nuria","family":"Izquierdo-Useros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Noguera-Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-5948","authenticated-orcid":false,"given":"Jorge","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chamorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-151X","authenticated-orcid":false,"given":"Marta","family":"Massanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100523_bib1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100523_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.medj.2021.01.005","article-title":"Stable neutralizing antibody levels 6\u00a0months after mild and severe COVID-19 episodes","volume":"2","author":"Pradenas","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.xcrm.2022.100523_bib3","first-page":"371","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8\u00a0months after infection","volume":"80","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100523_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2020.10.108","article-title":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","volume":"538","author":"Carrillo","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2022.100523_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in Health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100523_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"AD","year":"1999","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with Novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jinf.2020.03.012","article-title":"Profile of specific antibodies to SARS-CoV-2: the first report","volume":"81","author":"Xiao","year":"2020","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.xcrm.2022.100523_bib12","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib13","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s41598-021-81862-9","article-title":"SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity","volume":"11","author":"Trinit\u00e9","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2022.100523_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib15","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/cid\/ciaa721","article-title":"Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients","volume":"71","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti\u2013SARS-CoV-2 antibodies in Persons with mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100523_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100523_bib19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"Wheatley","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100523_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib21","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"7867","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100523_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100523_bib24","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","article-title":"The time course of the immune response to experimental coronavirus infection of man","volume":"105","author":"Callow","year":"1990","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.xcrm.2022.100523_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3201\/eid2504.181595","article-title":"Middle east respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia","volume":"25","author":"Al-Abdely","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3201\/eid2307.170310","article-title":"MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015","volume":"23","author":"Choe","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/cid\/civ951","article-title":"Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection","volume":"62","author":"Corman","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1086\/423286","article-title":"Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection","volume":"190","author":"Nie","year":"2004","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib30","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3201\/eid2112.151421","article-title":"Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea","volume":"21","author":"Park","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18450-4","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100523_bib33","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","article-title":"Disappearance of antibodies to SARS-associated coronavirus after recovery","volume":"357","author":"Cao","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100523_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/00365548.2011.560184","article-title":"Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients","volume":"43","author":"Liu","year":"2011","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib35","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3201\/eid2705.204056","article-title":"Longevity of middle east respiratory syndrome coronavirus antibody responses in humans, Saudi Arabia","volume":"27","author":"Alshukairi","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib36","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/22221751.2020.1761267","article-title":"Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg","volume":"9","author":"Anderson","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.xcrm.2022.100523_bib37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of antibodies against middle east respiratory syndrome coronavirus","volume":"22","author":"Payne","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.xcrm.2022.100523_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","article-title":"Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance","volume":"11","author":"Mo","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.xcrm.2022.100523_bib39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/22221751.2021.1872352","article-title":"Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerg","volume":"10","author":"Kim","year":"2021","journal-title":"Microbes Infect."},{"key":"10.1016\/j.xcrm.2022.100523_bib40","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2022.100523_bib41","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/nsr\/nwab006","article-title":"COVID-19 reinfection in the presence of neutralizing antibodies","volume":"8","author":"Zhang","year":"2021","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.xcrm.2022.100523_bib42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/v13040661","article-title":"Sars-cov-2 reinfection in a healthcare worker despite the presence of detectable neutralizing antibodies","volume":"13","author":"Brehm","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2022.100523_bib43","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41564-021-00974-0","article-title":"Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern","volume":"6","author":"Dupont","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.xcrm.2022.100523_bib44","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1038\/s41467-021-24979-9","article-title":"Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses","volume":"12","author":"Ortega","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100523_bib45","article-title":"Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are 1 robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines","author":"Muena","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2022.100523_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"Gallais","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.xcrm.2022.100523_bib47","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1002\/eji.202149535","article-title":"Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans","volume":"51","author":"Haveri","year":"2021","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.xcrm.2022.100523_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100523_bib49","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","article-title":"Long-lived plasma cells: a mechanism for maintaining persistent antibody production","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"0","author":"Khodadadi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.23.021704.115723","article-title":"Maintenance of serum antibody levels","volume":"23","author":"Manz","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2022.100523_bib54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4049\/jimmunol.92.5.673","article-title":"An autoradiographic study of plasma cell and lymphocyte survival in rat popliteal lymph nodes","volume":"92","author":"Miller","year":"1964","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2017.03.006","article-title":"Plasma cell and memory B cell differentiation from the germinal center","volume":"45","author":"Suan","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2022.100523_bib56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.xcrm.2022.100523_bib57","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100523_bib58","doi-asserted-by":"crossref","first-page":"103626","DOI":"10.1016\/j.ebiom.2021.103626","article-title":"Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients","volume":"73","author":"Carre\u00f1o","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2022.100523_bib59","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/v13061135","article-title":"Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals","volume":"13","author":"Trinit\u00e9","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2022.100523_bib60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2022.100523_bib61","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100523_bib62","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1016\/j.vaccine.2011.05.016","article-title":"A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity","volume":"29","author":"S\u00e1nchez-Palomino","year":"2011","journal-title":"Vaccine"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:13:57Z","timestamp":1778919237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666379122000234"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100523","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.12.21261921","asserted-by":"object"}]},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100523"}}